Drug Development
Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The lawsuit alleges that Ocugen made “materially false and misleading statements” about its operations and compliance policies.
American health authorities have a dilemma. On one hand, COVID-19 booster shots for immunocompromised patients dramatically increase their immune response. On the other, in many parts of the world only a tiny fraction of the population have received even one dose of any COVID-19 vaccine. So, who should get the vaccines?
The drug is a nucleoside reverse transcriptase translocation inhibitor, with the results presented at the virtual 11th International AIDS Society Conference on HIV Science.
The recent survival results of Masitinib will help (ALS) patients to live longer. AB Science has successfully established the sweet spot for masitinib in ALS.
Genentech’s Hemlibra showed no new safety signals and continued to deliver consistent bleeding control in the final analysis of a long-term, late-stage hemophilia A study.
The firm would be moving forward to Phase III for the treatment of hypertrophic cardiomyopathy, which is expected to commence before the end of 2021.
The CDC Advisory Committee on Immunization Practices is planning a meeting in October to recommend the vaccine’s use in adults.
Meissa’s intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting.
Boston-based Alexion Pharmaceuticals announced positive topline data from its Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.
It was a moderately busy mid-summer week for clinical trial news. Here’s a look.